

# A&I

## ANÄSTHESIOLOGIE & INTENSIVMEDIZIN

Offizielles Organ: Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI)  
Berufsverband Deutscher Anästhesisten e.V. (BDA)  
Deutsche Akademie für Anästhesiologische Fortbildung e.V. (DAAF)  
Organ: Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI)



**Behcet's disease**

**Biliary atresia**

orphan**a**nesthesia

a project of the German Society  
of Anaesthesiology and Intensive Care Medicine

**SUPPLEMENT NR. 10 | 2019**

## OrphanAnesthesia –

### ein krankheitsübergreifendes Projekt des Wissenschaftlichen Arbeitskreises Kinderanästhesie der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e.V.

Ziel des Projektes ist die Veröffentlichung von Handlungsempfehlungen zur anästhesiologischen Betreuung von Patienten mit seltenen Erkrankungen. Damit will Orphan Anesthesia einen wichtigen Beitrag zur Erhöhung der Patientensicherheit leisten.

Patienten mit seltenen Erkrankungen benötigen für verschiedene diagnostische oder therapeutische Prozeduren eine anästhesiologische Betreuung, die mit einem erhöhten Risiko für anästhesieassoziierte Komplikationen einhergehen. Weil diese Erkrankungen selten auftreten, können Anästhesisten damit keine Erfahrungen gesammelt haben, so dass für die Planung der Narkose die Einholung weiterer Information unerlässlich ist. Durch vorhandene spezifische Informationen kann die Inzidenz von mit der Narkose assoziierten Komplikationen gesenkt werden. Zur Verfügung stehendes Wissen schafft Sicherheit im Prozess der Patientenversorgung.

Die Handlungsempfehlungen von OrphanAnesthesia sind standardisiert und durchlaufen nach ihrer Erstellung einen Peer-Review-Prozess, an dem ein Anästhesist sowie ein weiterer Krankheitsexperte (z.B. Pädiater oder Neurologe) beteiligt sind. Das Projekt ist international ausgerichtet, so dass die Handlungsempfehlungen grundsätzlich in englischer Sprache veröffentlicht werden.

Ab Heft 5/2014 werden im monatlichen Rhythmus je zwei Handlungsempfehlungen als Supplement der A&I unter [www.ai-online.info](http://www.ai-online.info) veröffentlicht. Als Bestandteil der A&I sind die Handlungsempfehlungen damit auch zitierfähig. Sonderdrucke können gegen Entgelt bestellt werden.

## OrphanAnesthesia –

### a common project of the Scientific Working Group of Paediatric Anaesthesia of the German Society of Anaesthesiology and Intensive Care Medicine

The target of OrphanAnesthesia is the publication of anaesthesia recommendations for patients suffering from rare diseases in order to improve patients' safety. When it comes to the management of patients with rare diseases, there are only sparse evidence-based facts and even far less knowledge in the anaesthetic outcome. OrphanAnesthesia would like to merge this knowledge based on scientific publications and proven experience of specialists making it available for physicians worldwide free of charge.

All OrphanAnesthesia recommendations are standardized and need to pass a peer review process. They are being reviewed by at least one anaesthesiologist and another disease expert (e.g. paediatrician or neurologist) involved in the treatment of this group of patients.

The project OrphanAnesthesia is internationally oriented. Thus all recommendations will be published in English.

Starting with issue 5/2014, we'll publish the OrphanAnesthesia recommendations as a monthly supplement of A&I (Anästhesiologie & Intensivmedizin). Thus they can be accessed and downloaded via [www.ai-online.info](http://www.ai-online.info). As being part of the journal, the recommendations will be quotable. Reprints can be ordered for payment.

**Bisher in A&I publizierte Handlungsempfehlungen finden Sie unter:**

[www.ai-online.info/Orphsuppl](http://www.ai-online.info/Orphsuppl)  
[www.orphananesthesia.eu](http://www.orphananesthesia.eu)

**A survey of until now in A&I published guidelines can be found on:**

[www.ai-online.info/Orphsuppl](http://www.ai-online.info/Orphsuppl)  
[www.orphananesthesia.eu](http://www.orphananesthesia.eu)

#### Projektleitung

**Prof. Dr. Tino Münster, MHBA**

Chefarzt  
Klinik für Anästhesie und  
operative Intensivmedizin  
Krankenhaus Barmherzige  
Brüder Regensburg  
Prüfeninger Straße 86  
93049 Regensburg,  
Deutschland

Tel.: 0941 369-2350

E-Mail: [Tino.Muenster@barmherzige-regensburg.de](mailto:Tino.Muenster@barmherzige-regensburg.de)

# orphananesthesia

## Anaesthesia recommendations for Biliary atresia

**Disease name:** Biliary atresia

**ICD 10:** Q44.2

**Synonyms:** Extrahepatic biliary atresia, familial extrahepatic biliary atresia, idiopathic extrahepatic biliary atresia

**Disease summary:** Biliary atresia (BA) is a rare and fatal progressive inflammatory disease of infancy affecting the intra and extrahepatic bile ducts leading to cholestasis, fibrosis and cirrhosis. It has a varying incidence ranging from 1:10,000 to 1:20,000 live births. Persistent jaundice for more than 2 weeks in a term infant mandates evaluation for BA. Without medical intervention, BA leads to liver failure and ultimately death within the first two years of life.

Kasai's portoenterostomy (KPE) is the first line of treatment which aims at restoring the forward flow of bile from the liver into the intestines using a jejunal Roux-en-Y limb, which is anastomosed to the porta hepatis after resection of biliary remnants. Orthotopic liver transplantation (OLT) is reserved for children with a failed Kasai's procedure. Kasai's portoenterostomy procedure and liver transplantation along with adjuvant medical therapy and nutritional support have improved the prognosis of infants with BA and survival up to adulthood has been documented. The main anaesthetic concerns during portoenterostomy are conduct of safe anaesthesia in an infant with mild to moderate derangement of liver function scheduled for a lengthy upper abdominal wall laparotomy. This necessitates meticulous attention to patient's intraoperative fluid status, temperature regulation, glucose metabolism and provision of adequate perioperative analgesia in the presence of a compromised and dysfunctional liver. Surgical manoeuvres causing transient obstruction to inferior vena caval blood flow and hypotension need to be anticipated and managed appropriately.

---

Medicine is in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnosis is wrong

---



Find more information on the disease, its centres of reference and patient organisations on Orpha.net: [www.orpha.net](http://www.orpha.net)

► **Citation:** Ganigara A: Biliary atresia. Anästh Intensivmed 2019;60:S440–S447.  
DOI: 10.19224/ai2019.S440

---

### Typical surgery

---

Liver biopsy and intraoperative cholangiogram, Kasai's portoenterostomy, upper gastrointestinal endoscopy, orthotopic liver transplantation.

---

### Type of anaesthesia

---

There are no current guidelines regarding the administration of general and or regional anaesthesia in children with BA.

Anaesthetic agents with minimal hepatotoxic effects need to be administered. Changes in the body fluid compartment or low serum albumin levels can affect the drug distribution and the available free fraction of drugs. Hepatic artery blood flow, presence of portosystemic shunts and decreased hepatic enzyme activity can influence the pharmacokinetics of anaesthetic drugs.

Central neuraxial blocks are safe provided there is no coagulopathy, thrombocytopenia and portal hypertension-induced epidural varices.

---

### Necessary additional pre-operative testing (beside standard care)

---

A baseline liver function test including serum albumin, glucose, prothrombin time and its international normalised ratio are needed to know the severity of underlying liver dysfunction.

Infants with BA associated with BASM (biliary atresia splenic malformation) can have associated anomalies of the spleen, situs inversus, absent vena cava and other cardiac anomalies. Pulmonic stenosis and Tetralogy of Fallot are also associated cardiac anomalies which need to be screened by echocardiography.

---

### Particular preparation for airway management

---

Precautions in anticipation of a potentially full stomach need to be taken if there is abdominal distension due to ascites or hepatosplenomegaly. Diaphragmatic splinting can decrease the functional residual capacity and cause early small airway closure leading to rapid oxygen desaturation; thus, the need for adequate oxygenation during induction and emergence from anaesthesia.

---

### Particular preparation for transfusion or administration of blood products

---

Vitamin K administration is mandatory in infants with cholestasis. Vitamin K, a fat soluble vitamin necessary for hepatic synthesis of coagulation factors II, VII, X and IX is not absorbed in this set of patients due to impaired secretion of bile salts in the intestine. Vitamin K administration promptly corrects the coagulopathy; however, vitamin K unresponsive coagulopathy indicates severe hepatocellular failure affecting the synthetic function of the liver or could indicate underlying sepsis and undernutrition. In case of documented coagulopathy, appropriate blood products need to be administered.

Although blood loss during surgery is minimal, the provision of adequate units of packed red blood cells and blood components to correct coagulopathy has to be ensured before surgery.

---

#### **Particular preparation for anticoagulation**

---

No particular recommendation for anticoagulation in patients with BA.

---

#### **Particular precautions for positioning, transportation and mobilisation**

---

No recommendations at present.

Slight head-up position can be employed if there is abdominal distension to minimise respiratory compromise and avoid aspiration.

---

#### **Interactions of chronic disease and anaesthesia medications**

---

No recommendations present.

---

#### **Anaesthetic procedure**

---

Anaesthesia has to be tailored based on the patient's age, underlying liver dysfunction, cholestasis and surgical severity. Isoflurane with its ability to increase the arterial hepatic blood flow with minimal decrease in total hepatic blood flow is considered to be safe. Sevoflurane and desflurane can also be safely used as they are devoid of any hepatotoxic effects with minimal metabolism. Atracurium and cisatracurium have definite advantages over other neuromuscular blockers because of their unique metabolism, and thus are favoured.

The hepatic synthetic and metabolic functions are relatively unimpaired till late stages of BA and thus doses of opioid analgesics remain unchanged. The hepatic artery buffer system probably responds to a decrease in portal venous blood flow by a compensatory increase in hepatic arterial blood flow in early stages of BA. Morphine in the dose of 10-40 µg/kg/hr has been used safely for infants with BA for post-operative analgesia. In children with mild to moderate Child Pugh scoring, tramadol can be used, but the dose needs to be halved and the dosing interval increased from 6 hours to 12 hours. Similar dose reductions are recommended for acetaminophen if used as an adjuvant analgesic.

The metabolism of propofol is also not significantly affected in infants with BA, with extrahepatic metabolism playing a more significant role in the overall elimination of propofol in this subset of population.

The metabolism of bupivacaine could be affected due to decreased clearance along with a low level of serum alpha1 acid glycoprotein causing an increase in the unbound fraction of bupivacaine leading to cardiovascular toxicity. A maximum dose of 0.25mg/kg/hr in infants younger than 4 months and a maximum of 0.3mg/kg/hr in infants older than 4 months has been recommended for post-operative continuous epidural infusion of bupivacaine in infants with BA.

Nitrous oxide is avoided to prevent gut distension hampering abdominal wall closure. Controlled ventilation avoiding high airway pressures with the maintenance of normocarbina is essential to avoid changes in hepatic and portal blood flow.

---

#### Particular or additional monitoring

Internal jugular venous access and/or wide bore peripheral lines in the upper limb is essential for monitoring the central venous pressure as well as managing major fluid shifts caused during KPE. The critical surgical event during KPE is exteriorization of the liver from the abdominal cavity to explore the porta hepatis, which results in a sudden drop in blood pressure due to kinking of inferior vena cava and subsequent obstruction of venous return. Change in the ECG amplitude (Brody's effect) or a reduction in the blood pressure/central venous pressure can be used to recognize this event. An intra-arterial catheter is recommended for continuous monitoring of blood pressure and blood gas sampling in selected cases. Hourly urine output monitoring can also help in fluid management in long cases.

Intraoperative blood-sugar monitoring is mandatory. Dextrose containing fluids need to be judiciously used if hypoglycaemia is documented or if the synthetic function of liver is suspected to be hampered. The core temperature needs to be monitored and measures to prevent hypothermia have to be instituted.

---

#### Possible complications

Extensive fluid loss and surgical manoeuvres leading to inferior vena caval kinking can lead to a transient but significant fall in blood pressure which can be easily managed by a fluid boluses and added vasopressor therapy.

The large surface to volume ratio of infants, lack of adequate subcutaneous adipose tissue, exposure of body cavities to low environmental temperatures, infusion of cold fluids and ventilation with dry gases can increase the risk of perioperative hypothermia.

---

#### Post-operative care

Post-operatively, infants with BA need High Dependency Unit care. Cardiovascular toxicity arising from continuous infusions of local anaesthetic needs to be strongly suspected in infants with an epidural catheter in situ for pain management. A continuous post-operative intravenous opioid infusion for pain management necessitates monitoring of the sedation score and the respiratory rate to detect respiratory depression.

Episodes of ascending cholangitis can complicate the post-operative course.

---

### **Disease-related acute problems and effect on anaesthesia and recovery**

---

Infants with BA who seek medical attention later in infancy can present in acute sepsis with coagulopathy which needs prompt emergent management.

BA needs to be differentiated from other infectious, congenital, metabolic and genetic causes of neonatal cholestasis causing pathological persistent conjugated hyperbilirubinaemia. Timely recognition and surgical intervention is crucial for determining long-term survival of infants with BA.

---

### **Ambulatory anaesthesia**

---

No current recommendations exist.

Children with BA can present for upper gastrointestinal variceal treatment in the form of sclerotherapy or variceal ligation. General anaesthesia and securing the airway with tracheal intubation is recommended for all procedures except the very shortest duration surgical procedures. Gut distension during endoscopy can lead to catastrophic respiratory embarrassment and needs to be avoided.

---

### **Obstetrical anaesthesia**

---

With successful KPE and OLT, survival up to child-bearing age has been documented. Pregnancy is considered a high risk and, although not contraindicated, several groups recommend managing pregnancy after risk assessment for hepatic failure in women with BA post KPE or OLT. Complications of portal hypertension, hypersplenism, gastrointestinal variceal bleeding, episodes of cholangitis, added cholestatic insult and extensive varices on the anterior abdominal wall can influence the course of pregnancy and attendant medical treatment. A multidisciplinary team work to manage parturient women with BA is recommended.

## References

1. Davenport M. Biliary atresia: From Australia to zebrafish. *J Pediatr Surg* 2016;51:200–205
2. Kelly DA, Davenport M. Current management of biliary atresia. *Arch Dis Child* 2007;92:1132–1135
3. Hartley JL, Davenport M. Biliary atresia. *Lancet* 2009;37:1704–1713
4. Green DW, Howard ER, Davenport M. Anesthesia, perioperative management and outcome of correction of extrahepatic biliary atresia in the infant: a review of 50 cases in the King's College Hospital series. *Paediatr Anaesth* 2000;10:581–589
5. Ganigara A, Ramavakoda CY, Bindu, Sanket B, Jadhav V, Aihole JS. Anesthetic management and perioperative outcome of infants with Biliary atresia: a retrospective review of 40 cases from a tertiary care pediatric institute in India. *Indian J Clin Anaesth* 2016;3:62–68
6. Zagory JA, Nguyen MV, Wang KS. Recent advances in the pathogenesis and management of Biliary atresia. *Curr Opin Pediatr* 2015;27(3):389–394
7. Van Obbergh LJ, Verbeeck RK, Michel I, Lim S, Veyckemans F. Extrahepatic metabolism of sevoflurane in children undergoing orthotopic liver transplantation. *Anesthesiology* 2000;92:683–686
8. Wang X, Qiao ZW, Zhou ZJ, Zhuang PJ, Zheng S. Post operative morphine concentration in infants with or without biliary atresia and its association with hepatic blood flow. *Anesthesia* 2014;69:583–590
9. Seefelder C, Lillehei CW. Epidural analgesia for patients undergoing hepatic portoenterostomy (Kasai procedure). *Paediatr Anaesth* 2002;12(2):193–195
10. Meunier JF, Goujard E, Dubouset AM, Samii K, Mazoit JX. Pharmacokinetics of bupivacaine after continuous epidural infusion in infants with and without biliary atresia. *Anesthesiology* 2001;95:87–95
11. Vila R, Miguel E, Montferrer N, Barat G, Fernandez C, Gonzalez E, et al. Respiratory depression following epidural morphine in an infant of three months of age. *Paediatr Anaesth* 1997;7:61–64
12. Simpson DA, Green DW. Use of atracurium during major abdominal surgery in infants with hepatic dysfunction from biliary atresia. *Br J Anaesth* 1986;58:1214–1217
13. Bromley P, Bennett J. Anaesthesia for children with liver disease. Continuing education in anaesthesia, *Anaesth Crit Care Pain Med* 2014;14:201–212
14. Raouf AA, Van Obbergh LJ, Verbeeck RK. Propofol pharmacokinetics in children with biliary atresia. *Br J Anaesth* 1995;74:46–49
15. Jawan B, Tseng CC, Chen YS, Wang CC, Cheng YF, Huang TL, et al. Is there any difference in anesthetic management of biliary atresia and glycogen storage disorder disease patients undergoing liver transplantation. *J Surg Res* 2005;126:82–85
16. Ganigara A, Ramavakoda CY. Clinical evidence of Brody's effect in infants undergoing Kasai's portoenterostomy for Biliary Atresia. *Paediatr Anaesth* 2014;24:1193–1194
17. Jacob R. Anaesthesia for biliary atresia and hepatectomy in paediatrics. *Indian J Anaesth* 2012;56:479–484
18. O'Sullivan OE, Crosby D, Byrne B, Regan C. Pregnancy complicated by Portal Hypertension Secondary to Biliary Atresia. *Case Rep Obstet Gynecol* 2013;26:2013
19. Kendigelen P, Tutuncu AC, Erbabacan SE, Kaya G, Altindas F. Anaesthetic management of a patient with synchronous Kartegener syndrome and Biliary Atresia. *Turk J Anaesth Reanim* 2015;43:205–208
20. Hammer G, Hall S, Davis PJ, Cladis FP. Anesthesia for general abdominal, thoracic, urologic and bariatric surgery. In: Motoyama EK, Davis PJ, Cladis FP. *Smith's anesthesia for infants and children*. 8th ed., Philadelphia: Elsevier Mosby 2006, publ. 2011
21. Bijl EJ, Bharwani KD, Houwen RH, de Man RA. The long-term outcome of the Kasai operation in patients with biliary atresia: a systematic review. *Neth J Med* 2013;71:170–173
22. Feldman AG, Sokol RJ. Neonatal cholestasis. *Neoreviews* 2013;14(2):63–73
23. Suchy FJ. Neonatal cholestasis. *Pediatr Rev* 2004;25:388–395
24. Wildhaber BE, Coran AG, Drongowski RA, Hirschl RB, Geiger JD, Lelli JL, et al. The Kasai portoenterostomy for biliary atresia: a review of a 27-year experience with 81 patients. *J Paediatr Surg* 2003;38:1480–1485
25. Wildhaber BE. Biliary atresia: 50 years after the first Kasai. *ISRN Surg* 2012;2012:132089



26. Sundaram SS, Alonso EM, Haber B, Magee JC, Fredericks E, Kamath B, et al. Health related quality of life in patients with biliary atresia surviving with their native liver. *J Pediatr* 2013;163:1052–1057
27. Kumagi T, Drenth JPH, Guttman O, Ng V, Lilly L, Therapondos G, et al. Biliary atresia and survival into adulthood without transplantation: a collaborative multicentre clinic review. *Liver Int* 2012;32:510–518.

---

**Date last modified: August 2017**

---

*This recommendation was prepared by:*

**Author(s)**

**Anuradha Ganigara**, Anaesthesiologist, Indira Gandhi Institute of Child Health, Bangalore, Karnataka, India  
anuradhasudhir@gmail.com

**Disclosure(s)** The author has no financial or other competing interest to disclose. This recommendation was unfunded.

*This recommendation was reviewed by:*

**Reviewer 1**

**Peter Bromley**, Consultant Paediatric Anaesthesiologist, Department of Anaesthesia, Birmingham Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom  
peter.bromley@bch.nhs.uk

**Reviewer 2**

**Krishna Kumar Govindarajan**, Associate Professor Paediatric Surgery, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Puducherry, India  
sasisang@rediffmail.com

**Disclosure(s)** The reviewers have no financial or other competing interest to disclose.

---

## Herausgeber



### DGAI

Deutsche Gesellschaft  
für Anästhesiologie und  
Intensivmedizin e.V.  
Präsident: Prof. Dr.  
R. Rossaint, Aachen



### BDA

Berufsverband Deutscher  
Anästhesisten e.V.  
Präsident: Prof. Dr.  
G. Geldner, Ludwigsburg



### DAF

Deutsche Akademie  
für Anästhesiologische  
Fortbildung e.V.  
Präsident: Prof. Dr.  
F. Wappler, Köln

## Schriftleitung

Präsident/in der Herausgeberverbände  
Gesamtschriftleiter/Editor-in-Chief:  
Prof. Dr. Dr. Kai Zacharowski, Frankfurt  
Stellvertretender Gesamtschriftleiter/  
Deputy Editor:  
Prof. Dr. T. Volk, Homburg/Saar  
CME-Schriftleiter/CME-Editor:  
Prof. Dr. W. Zink, Ludwigshafen

## Redaktionskomitee/Editorial Board

Prof. Dr. G. Beck, Wiesbaden  
Dr. iur. E. Biermann, Nürnberg  
Prof. Dr. H. Bürkle, Freiburg  
Prof. Dr. B. Ellger, Dortmund  
Prof. Dr. K. Engelhard, Mainz  
Prof. Dr. M. Fischer, Göppingen  
Priv.-Doz. Dr. T. Iber, Baden-Baden  
Prof. Dr. U. X. Kaisers, Ulm  
Prof. Dr. T. Loop, Freiburg  
Prof. Dr. W. Meißner, Jena  
Prof. Dr. C. Nau, Lübeck  
Dr. M. Rähmer, Mainz  
Prof. Dr. A. Schleppers, Nürnberg  
Prof. Dr. M. Thiel, Mannheim  
Prof. Dr. F. Wappler, Köln  
Prof. Dr. M. Weigand, Heidelberg

## Redaktion/Editorial Staff

Carolin Sofia Kopp B.A. &  
Dipl.-Sozw. Holger Sorgatz  
Korrespondenzadresse: Roritzerstraße 27 |  
90419 Nürnberg | Deutschland  
Tel.: 0911 9337812 | Fax: 0911 3938195  
E-Mail: anaesth.intensivmed@dgai-ev.de

## Verlag & Druckerei

### Aktiv Druck & Verlag GmbH

An der Lohwiese 36 |  
97500 Ebelsbach | Deutschland  
www.aktiv-druck.de

### Geschäftsführung

Wolfgang Schröder | Jan Schröder |  
Nadja Schwarz  
Tel.: 09522 943560 | Fax: 09522 943567  
E-Mail: info@aktiv-druck.de

### Anzeigen | Vertrieb

Pia Engelhardt  
Tel.: 09522 943570 | Fax: 09522 943577  
E-Mail: anzeigen@aktiv-druck.de

### Verlagsrepräsentanz

Jürgen Distler  
Roritzerstraße 27, 90419 Nürnberg  
Tel.: 0171 9432534 | Fax: 0911 3938195  
E-Mail: jdistler@bda-ev.de

### Herstellung | Gestaltung

Manfred Wuttke | Stefanie Triebert  
Tel.: 09522 943571 | Fax: 09522 943577  
E-Mail: ai@aktiv-druck.de

### Titelbild

Dipl.-Designerin Monique Minde,  
Nürnberg

### Erscheinungsweise 2019

Der 60. Jahrgang erscheint jeweils zum  
Monatsanfang, Heft 7/8 als Doppelausgabe.

### Bezugspreise (inkl. Versandkosten):

- Einzelhefte 30,- i
- Jahresabonnement:
  - Europa (ohne Schweiz) 258,- i
  - (inkl. 7 % MwSt.)
  - Schweiz 266,- i
  - Rest der Welt 241,- i

### Mitarbeiter aus Pflege, Labor, Studenten und Auszubildende (bei Vorlage eines entsprechenden Nachweises)

- Europa (ohne Schweiz) 94,- i
- (inkl. 7 % MwSt.)
- Schweiz 90,- i
- Rest der Welt 94,- i

**Für Mitglieder der DGAI und/oder  
des BDA ist der Bezug der Zeitschrift  
im Mitgliedsbeitrag enthalten.**

## Allgemeine Geschäfts- und Liefer- bedingungen

Die allgemeinen Geschäfts- und Liefer-  
bedingungen entnehmen Sie bitte dem  
Impressum auf [www.ai-online.info](http://www.ai-online.info)

Indexed in **Current Contents®/Clinical  
Medicine, EMBASE/Excerpta Medica;  
Medical Documentation Service;  
Research Alert; Sci Search; SUBIS  
Current Awareness in Biomedicine;  
VINITI: Russian Academy of Science.**

## Nachdruck | Urheberrecht

Die veröffentlichten Beiträge sind urhe-  
berrechtlich geschützt. Jegliche Art von  
Vervielfältigungen – sei es auf mechani-  
schem, digitalem oder sonst möglichem  
Wege – bleibt vorbehalten. Die Aktiv  
Druck & Verlags GmbH ist allein auto-  
risiert, Rechte zu vergeben und Sonder-  
drucke für gewerbliche Zwecke, gleich  
in welcher Sprache, herzustellen. An-  
fragen hierzu sind nur an den Verlag zu  
richten. Jede im Bereich eines gewerbli-  
chen Unternehmens zulässig hergestellte  
oder benutzte Kopie dient gewerblichen  
Zwecken gem. § 54 (2) UrhG. Die Wie-  
dergabe von Gebrauchsnamen, Handels-  
namen, Warenbezeichnungen usw. in  
dieser Zeitschrift berechtigt auch ohne  
besondere Kennzeichnung nicht zu der  
Annahme, dass solche Namen im Sinne  
der Warenzeichen- und Markenschutz-  
Gesetzgebung als frei zu betrachten wä-  
ren und daher von jedermann benutzt  
werden dürften.

## Wichtiger Hinweis

Für Angaben über Dosierungsanwei-  
sungen und Applikationsformen kann  
vom Verlag und den Herausgebern keine  
Gewähr übernommen werden. Derartige  
Angaben müssen vom jeweiligen An-  
wender im Einzelfall anhand anderer  
Literaturstellen auf ihre Richtigkeit über-  
prüft werden. Gleiches gilt für berufs-  
und verbandspolitische Stellungnahmen  
und Empfehlungen.

Die Beiträge aus der A&I finden Sie online unter: [www.ai-online.info](http://www.ai-online.info)

# CONTACT US

Please do not hesitate to contact us. We will be glad to answer and provide further information to you at any time.

.....  
Name

.....  
First Name

.....  
Department / Hospital

.....  
Place

.....  
Telephone

.....  
E-Mail

.....  
Date / Signature

Please contact me for further information

I would like to participate in the project

## ADDRESS

German Society of Anaesthesiology and  
Intensive Care Medicine  
Ursula Homberg  
Roritzerstrasse 27 | 90419 Nuremberg | Germany  
Tel.: +49-911-9337828 | Fax: +49-911-3938195  
Email: uhomberg@orphananesthesia.eu